In conclusion, we believe that the proposed afatinib plus bevacizumab regimen after treatment with osimertinib trial will provide clinically significant data that will aid the development of novel treatment strategies for patients with EGFR‐mutated lung cancer who develop therapy resistance after first‐line treatment with osimertinib. This evidence concerns the gene EGFR and lung cancer.